A potential Covid-19 vaccine being developed by China National Biotech Group (CNBG) unit Beijing Institute of Biologic Products demonstrated to be safe and triggered immune responses in a combined early and mid-stage test in humans, according to researchers.
Dubbed BBIBP-CorV, the vaccine is already approved for an emergency inoculation programme in China targeting essential workers and others at high infection risk.
According to the World Health Organization (WHO), BBIBP-CorV is one of at least ten coronavirus vaccine programmes progressed to Phase III trials worldwide, with four among these led by Chinese scientists.
The dose-escalation, randomised, double-blind, placebo-controlled, Phase I / II trial of BBIBP-CorV enrolled over 600 healthy participants aged between 18 and 80 years.
The Covid-19 vaccine trial was conducted between 29 April and 30 July in a single centre in China.
Data from the trials showed that giving two injections of BBIBP-CorV at three different doses was safe and well-tolerated in all participants.
Throughout the trial, a robust humoral immune response was observed in all vaccine recipients.
In participants aged 60 and above, antibody levels were lower and took longer to increase significantly than those in younger recipients.